Experimental Pharmacological Approaches to Reverse Impaired Awareness of Hypoglycemia-a Review

Overview

Journal Front Pharmacol

Date 2024 Feb 7

PMID 38323079

Authors

Hiba Z Hashmi

Ameer Khowaja

Amir Moheet

Affiliations

Soon will be listed here.

Abstract

The colossal global burden of diabetes management is compounded by the serious complication of hypoglycemia. Protective physiologic hormonal and neurogenic counterregulatory responses to hypoglycemia are essential to preserve glucose homeostasis and avert serious morbidity. With recurrent exposure to hypoglycemic episodes over time, these counterregulatory responses to hypoglycemia can diminish, resulting in an impaired awareness of hypoglycemia (IAH). IAH is characterized by sudden neuroglycopenia rather than preceding cautionary autonomic symptoms. IAH increases the risk of subsequent sudden and severe hypoglycemic episodes in patients with diabetes. The postulated causative mechanisms behind IAH are complex and varied. It is therefore challenging to identify a single effective therapeutic strategy. In this review, we closely examine the efficacy and feasibility of a myriad of pharmaceutical interventions in preventing and treating IAH as described in clinical and preclinical studies. Pharmaceutical agents outlined include N-acetyl cysteine, GABA A receptor blockers, opioid receptor antagonists, AMP activated protein kinase agonists, potassium channel openers, dehydroepiandrosterone, metoclopramide, antiadrenergic agents, antidiabetic agents and glucagon.

References

Zhu W, Czyzyk D, Paranjape S, Zhou L, Horblitt A, Szabo G . Glucose prevents the fall in ventromedial hypothalamic GABA that is required for full activation of glucose counterregulatory responses during hypoglycemia. Am J Physiol Endocrinol Metab. 2010; 298(5):E971-7. PMC: 2867375. DOI: 10.1152/ajpendo.00749.2009. View

Palani G, Stortz E, Moheet A . Clinical Presentation and Diagnostic Approach to Hypoglycemia in Adults Without Diabetes Mellitus. Endocr Pract. 2022; 29(4):286-294. DOI: 10.1016/j.eprac.2022.11.010. View

Roederer M, Ela S, Staal F, Herzenberg L . N-acetylcysteine: a new approach to anti-HIV therapy. AIDS Res Hum Retroviruses. 1992; 8(2):209-17. DOI: 10.1089/aid.1992.8.209. View

McCrimmon R, Fan X, Cheng H, McNay E, Chan O, Shaw M . Activation of AMP-activated protein kinase within the ventromedial hypothalamus amplifies counterregulatory hormone responses in rats with defective counterregulation. Diabetes. 2006; 55(6):1755-60. DOI: 10.2337/db05-1359. View

Cruz A, Partridge K, Malekizadeh Y, Vlachaki Walker J, Potter P, Pye K . Brain Permeable AMP-Activated Protein Kinase Activator R481 Raises Glycaemia by Autonomic Nervous System Activation and Amplifies the Counterregulatory Response to Hypoglycaemia in Rats. Front Endocrinol (Lausanne). 2022; 12:697445. PMC: 8718766. DOI: 10.3389/fendo.2021.697445. View

Vele S, Milman S, Shamoon H, Gabriely I . Opioid receptor blockade improves hypoglycemia-associated autonomic failure in type 1 diabetes mellitus. J Clin Endocrinol Metab. 2011; 96(11):3424-31. PMC: 3205891. DOI: 10.1210/jc.2011-1723. View

Alquier T, Kawashima J, Tsuji Y, Kahn B . Role of hypothalamic adenosine 5'-monophosphate-activated protein kinase in the impaired counterregulatory response induced by repetitive neuroglucopenia. Endocrinology. 2006; 148(3):1367-75. DOI: 10.1210/en.2006-1039. View

Khunti K, Alsifri S, Aronson R, Cigrovski Berkovic M, Enters-Weijnen C, Forsen T . Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016; 18(9):907-15. PMC: 5031206. DOI: 10.1111/dom.12689. View

Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I . N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008; 64(5):361-8. DOI: 10.1016/j.biopsych.2008.03.004. View

10.

Raghu G, Berk M, Campochiaro P, Jaeschke H, Marenzi G, Richeldi L . The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Curr Neuropharmacol. 2020; 19(8):1202-1224. PMC: 8719286. DOI: 10.2174/1570159X19666201230144109. View

11.

Dagogo-Jack S, Rattarasarn C, Cryer P . Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes. 1994; 43(12):1426-34. DOI: 10.2337/diab.43.12.1426. View

12.

Chan O, Zhu W, Ding Y, McCrimmon R, Sherwin R . Blockade of GABA(A) receptors in the ventromedial hypothalamus further stimulates glucagon and sympathoadrenal but not the hypothalamo-pituitary-adrenal response to hypoglycemia. Diabetes. 2006; 55(4):1080-7. DOI: 10.2337/diabetes.55.04.06.db05-0958. View

13.

Moheet A, Mangia S, Kumar A, Tesfaye N, Eberly L, Bai Y . Naltrexone for treatment of impaired awareness of hypoglycemia in type 1 diabetes: A randomized clinical trial. J Diabetes Complications. 2015; 29(8):1277-82. PMC: 4871128. DOI: 10.1016/j.jdiacomp.2015.08.004. View

14.

. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2016; 40(1):155-157. DOI: 10.2337/dc16-2215. View

15.

Henriksen M, Andersen H, Thorsteinsson B, Pedersen-Bjergaard U . Hypoglycemic Exposure and Risk of Asymptomatic Hypoglycemia in Type 1 Diabetes Assessed by Continuous Glucose Monitoring. J Clin Endocrinol Metab. 2018; 103(6):2329-2335. DOI: 10.1210/jc.2018-00142. View

16.

Farhat R, de Santana-Van Vliet E, Su G, Neely L, Benally T, Chan O . Carvedilol prevents impairment of the counterregulatory response in recurrently hypoglycaemic diabetic rats. Endocrinol Diabetes Metab. 2021; 4(2):e00226. PMC: 8029566. DOI: 10.1002/edm2.226. View

17.

Emral R, Pathan F, Cortes C, El-Hefnawy M, Goh S, Gomez A . Self-reported hypoglycemia in insulin-treated patients with diabetes: Results from an international survey on 7289 patients from nine countries. Diabetes Res Clin Pract. 2017; 134:17-28. DOI: 10.1016/j.diabres.2017.07.031. View

18.

Choat H, Martin A, Mick G, Heath K, Tse H, McGwin Jr G . Effect of gamma aminobutyric acid (GABA) or GABA with glutamic acid decarboxylase (GAD) on the progression of type 1 diabetes mellitus in children: Trial design and methodology. Contemp Clin Trials. 2019; 82:93-100. DOI: 10.1016/j.cct.2019.06.007. View

19.

Seino S, Miki T . Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol. 2003; 81(2):133-76. DOI: 10.1016/s0079-6107(02)00053-6. View

20.

George P, Tavendale R, Palmer C, McCrimmon R . Diazoxide improves hormonal counterregulatory responses to acute hypoglycemia in long-standing type 1 diabetes. Diabetes. 2015; 64(6):2234-41. DOI: 10.2337/db14-1539. View